Table 4.
Analysis according to NOAC
| Apixaban (n = 17) | Dabigatran (n = 19) | Rivaroxaban (n = 46) | p | |
|---|---|---|---|---|
| Clinical and demographic | ||||
| Age (years) | 76.9 (10.6) | 73.9 (9.2) | 72.1 (10.6) | 0.262 |
| Sex (male/female) | 8/9 | 15/4 | 26/20 | 0.119 |
| Creatinine (µmol/l) | 86 (30) | 90 (22) | 88 (21) | 0.879 |
| eGFR (ml/min/1.73) | 68 (19) | 71 (14) | 69 (15) | 0.832 |
| TEG indices | ||||
| R (min) | 6.7 (1.6) | 10.7 (5.9) | 8.5 (3.2) | 0.009a |
| K (min) | 1.7 (0.6) | 2.2 (0,9) | 2.0 (0.8) | 0.175 |
| Angle (°) | 64.4 (8.4) | 60.9 (7.9) | 63.5 (8.2) | 0.371 |
| MA (mm) | 66.2 (6.5) | 64.7 (5.8) | 65.1 (8.1) | 0.828 |
| TMA (min) | 25.0 (2.9) | 31.9 (7.7) | 28.5 (5.4) | 0.002a |
| G (d/s/103) | 10.3 (2.6) | 9.6 (2.6) | 10.0 (3.0) | 0.760 |
| E (d/s) | 205 (52) | 192 (53) | 199 (60) | 0.760 |
| TPI (s) | 74 (45–109) | 38 (30–63) | 56 (40–75) | 0.063 |
| A30 (mm) | 64.3 (6.6) | 62.5 (5.9) | 63.1 (8.1) | 0.756 |
| CL30 (%) | 97.2 (2.7) | 96.6 (2.2) | 96.8 (2.9) | 0.794 |
| LY30 | 0.4 (0.05–1.1) | 0.7 (0.3–2.0) | 0.6 (0.1–1.3) | 0.574 |
| A60 (mm) | 60.9 (6.2) | 58.7 (6.2) | 59.2 (7.9) | 0.631 |
| CL60 (%) | 92.0 (4.2) | 90.2 (3.8) | 91.0 (4.5) | 0.440 |
| LY60 (%) | 3.0 (1.4–4.2) | 3.7 (2.0–6.1) | 3.25 (1.8–4.9) | 0.772 |
| A (mm) | 60.9 (6.2) | 58.6 (6.2) | 59.4 (7.5) | 0.610 |
| CI (arbitrary units) | 2.0 (−0.8–2.8) | −2.0 (−5.0–0.1) | −0.7 (−2.5–0.7) | 0.002a |
| MPA indices | ||||
| L time (min) | 8.0 (7.6–9.2) | 23.0 (9.8–30.3) | 9.8 (7.8–12.1) | <0.001b |
| RCF (units/s) | 22.0 (20.0–29.0) | 28.5 (16.2–30.7) | 12.4 (7.0–15.3) | <0.001c |
| MOD (units) | 0.37 (0.09) | 0.27 (0.09) | 0.44 (0.13) | <0.001b |
| RCD (units/s) | 51.8 (13.9) | 42.6 (12.1) | 36.8 (17.3) | 0.005d |
| T50 (min) | 2.9 (0.45) | 3.3 (0.37) | 2.9 (0.75) | 0.161 |
Data presented as mean (standard deviation) or median (interquartile range). p values by analysis of variance or the Kruskall–Wallis test. eGFR estimated glomerular filtration rate. Between group analysis by Tukey’s post hoc test
a p < 0.05 between apixaban and dabigatran
b p < 0.05 between dabigatran and the two other groups
c p < 0.05 between rivaroxaban and the two other groups
d p < 0.05 between apixaban and rivaroxaban